Performance in Delivering Clinical Trials - Q1 2019/20

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date agreed to recruit target number of participants	Total Number Of patients Recruited at the agreed date	Total Number Of Study Participants Recruited	Date that the trial closed to recruitment	Reason For Closure Of Trial
		A randomized, blinded, parallel group, multi-center dose-finding									
		study, to assess the efficacy, safety and tolerability of different doses									
1 1		of tobramycin inhalation powder in patients with Non-Cystic Fibrosis			_			_			
16/EE/0358	212839	Bronchiectasis and pulmonary P. aeruginosa	Range Agreed	2	3	Date Agreed	01/03/2019	2	43343	02/01/1900	Withdrawn By Sponsor
	0.000.0	Long-term, open label, multicenter, extension study to evaluate the					05/00/004			00/04/4000	
17/EE/0502	218716	safety and tolerability of QCC374 in patients with PAH	Number Agreed	2	2	Date Agreed	05/09/2018	2	43348	02/01/1900	Recruitment Finished
		A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a									
18/NE/0104		Minimal Function Mutation (F/MF)	Number Agreed	1	1	Date Agreed	31/08/2018	2	43343	02/01/1900	Recruitment Finished
		Assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of the combination of GLPG2451 and GLPG2222, with or without GLPG2737, in adult									
18/NW/0006	237093	subjects with cystic fibrosis	Number Agreed	2	2	Date Agreed	25/05/2019	0	43312	00/01/1900	Recruitment Finished
17/EE/0472	235110	BAROSTIM NEO - Baroreflex Activation Therapy for Heart Failure	Number Agreed	8	8	Date Agreed	01/12/2019	1	43396	01/01/1900	Withdrawn By Sponsor
16/SC/0436	211806	A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy	Number Agreed	4	4	Date Agreed	19/10/2018	1	43336	01/01/1900	Recruitment Finished
10/30/0430	211000	EDOXABAN VERSUS STANDARD OF CARE AND THEIR EFFECTS ON CLINICAL OUTCOMES IN PATIENTS HAVING UNDERGONE TRANSCATHETER AORTIC VALVE IMPLANTATION ? IN ATRIAL	Number Agreed	1	-	Date Agreed	13/10/2010		43330	01/01/1300	Recruitment i misned
17/WS/0072	221444	FIBRILLATION	Number Agreed	10	10	Date Agreed	17/03/2018	0	43452	00/01/1900	Withdrawn By Sponsor
16/SC/0387	202827	Assessment of the effect of Positive Airway Pressure on energy and vitality in mild Obstructive Sleep Apnea patients. The Merge Study.	Number Agreed	10	10	Date Agreed	09/05/2019	13	43503	13/01/1900	Recruitment Finished
-		A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With									
18/NE/0103	241640	Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)	Number Agreed	2	2	Date Agreed	01/08/2018	2	43302	02/01/1900	Recruitment Finished
17/LO/0041	219676	CardioMEMS OUS	Range Agreed	1	10	Date Agreed	01/10/2019	1	43637	01/01/1900	Recruitment Finished
		A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks									
17/NW/0678	233267	in Subjects with Non-Cystic Fibrosis Bronchiectasis - T	Number Agreed	3	3	Date Agreed	31/03/2019	0	43573	00/01/1900	Recruitment Finished